The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Radhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 8×
“Cross-linking PD-1 by either PD-L1-Ig or PD-L2-Ig resulted in decreased proliferation, and decreased IFN-c, IL-10, IL-4, and IL-2 secretion from anti-CD3-stimulated T cells [24, 35], without an increase in cell death [35; and H.”
BackgroundInfluentialTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
Carreno, B. M., & Collins, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 896
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 3×
“The fact that PD-L1/PD-1 engagement can attenuate ICOS-positive costimulatory signals [5], that its negative signaling however can be negated by CD28 ligation or IL-2 [12], and the identification of a further negative regulatory receptor, BTLA [11, 75], indicates that the overall result from negative and positive cost…”
BackgroundOkazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Self-citationA fresh look at tumor immunosurveillance and immunotherapy
Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001) · Nature Immunology · doi:10.1038/86297 · Cited by 745
Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00005 · Cited by 701
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
Loke, P., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931259100 · Cited by 634
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 540
Salama, A. D., Chitnis, T., Imitola, J., Ansari, M. J. I., Akiba, H., Tushima, F., Azuma, M., Yagita, H., Sayegh, M. H., & Khoury, S. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022119 · Cited by 506
Nishimura, H. (1998) · International Immunology · doi:10.1093/intimm/10.10.1563 · Cited by 500
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance
Nishimura, H., & Honjo, T. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01888-9 · Cited by 474
Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Analysis and Expression of a Cloned Pre-T Cell Receptor Gene
Saint-Ruf, C., Ungewiss, K., Groettrup, M., Bruno, L., Fehling, H. J., & von Boehmer, H. (1994) · Science · doi:10.1126/science.7973703 · Cited by 403
PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., & Honjo, T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022235 · Cited by 392
Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M., & Wiendl, H. (2003) · PubMed · Cited by 381
Wintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R. M., Marincola, F. M., Leitman, S. F., Seipp, C. A., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00007 · Cited by 357
Immunoreceptor tyrosine-based inhibition motifs
Vivier, E., & Daëron, M. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80025-4 · Cited by 351
B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis
Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 326
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
Bennett, F., Luxenberg, D., Ling, V., Wang, I.-M., Marquette, K., Lowe, D., Khan, N., Veldman, G., Jacobs, K. A., Valge-Archer, V. E., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 281
Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., & Honjo, T. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00142-6 · Cited by 280
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells
Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 263
Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994) · Genomics · doi:10.1006/geno.1994.1562 · Cited by 253
The dual-function CD150 receptor subfamily: the viral attraction
Sidorenko, S. P., & Clark, E. A. (2003) · Nature Immunology · doi:10.1038/ni0103-19 · Cited by 252
Programmed Death-1 Targeting Can Promote Allograft Survival
Özkaynak, E., Wang, L., Goodearl, A., McDonald, K., Qin, S., O’Keefe, T., Duong, T., Smith, T., Gutierrez-Ramos, J.-C., Rottman, J. B., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6546 · Cited by 243
Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y.-X., & Schreiber, H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00480-6 · Cited by 236
Self-citationB7-H1 costimulation preferentially enhances CD28-independent T-helper cell function
Tamura, H., Dong, H., Zhu, G., Sica, G. L., Flies, D. B., Tamada, K., & Chen, L. (2001) · Blood · doi:10.1182/blood.v97.6.1809 · Cited by 218
Differential binding properties of B7-H1 and B7-DC to programmed death-1
Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H., Omura, K., Yagita, H., Pardoll, D. M., Chen, L., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01257-9 · Cited by 209
B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1
Petroff, M. G., Chen, L., Phillips, T. A., Azzola, D., Sedlmayr, P., & Hunt, J. S. (2003) · Biology of Reproduction · doi:10.1095/biolreprod.102.010058 · Cited by 197
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.
Singh, S., Ross, S. R., Acena, M., Rowley, D. A., & Schreiber, H. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.1.139 · Cited by 170
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection
Subudhi, S. K., Zhou, P., Yerian, L. M., Chin, R. K., Lo, J. C., Anders, R. A., Sun, Y., Chen, L., Wang, Y., Alegre, M.-L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19210 · Cited by 161
Shin, T., Kennedy, G., Gorski, K., Tsuchiya, H., Koseki, H., Azuma, M., Yagita, H., Chen, L., Powell, J., Pardoll, D., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030242 · Cited by 159
B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression
Trabattoni, D. (2003) · Blood · doi:10.1182/blood-2002-10-3065 · Cited by 159
Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R., & Mackensen, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.2161 · Cited by 158
Self-citationGao, W., Demirci, G., Strom, T. B., & Li, X. C. (2003) · Transplantation · doi:10.1097/01.tp.0000085010.39567.fb · Cited by 158
Peterson, A., Harlin, H., & Gajewski, T. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.144 · Cited by 154
Self-citationExpression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149
Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss, R., & Hanahan, D. (1998) · PubMed · Cited by 132
Blank, C. U., Brown, I., Marks, R., Nishimura, H., Honjo, T., & Gajewski, T. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4574 · Cited by 131
Self-citationWiendl, H., Mitsdoerffer, M., Schneider, D., Chen, L., Lochmüller, H., Melms, A., & Weller, M. (2003) · The FASEB Journal · doi:10.1096/fj.03-0039fje · Cited by 121
Gajewski, T. F., Fallarino, F., Ashikari, A., & Sherman, M. E. (2001) · PubMed · Cited by 113
Self-citationFrom defined human tumor antigens to effective immunization?
Boon, T., Gajewski, T. F., & Coulie, P. G. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80149-9 · Cited by 113
Self-citationD’Ambrosio, D., Fong, D. C., & Cambier, J. C. (1996) · Immunology Letters · doi:10.1016/s0165-2478(96)02653-3 · Cited by 106
BTLA: a new inhibitory receptor with a B7-like ligand
Carreno, B. M., & Collins, M. A. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.08.005 · Cited by 95
Oelke, M., Möhrle, U., Chen, J. L., Behringer, D. M., Cerundolo, V., Lindemann, A., & Mackensen, A. (2000) · PubMed · Cited by 86
Self-citationNormal Responsiveness of CTLA-4-Deficient Anti-Viral Cytotoxic T Cells
Bachmann, M. F., Waterhouse, P. D., Speiser, D. E., McKall-Faienza, K., Mak, T. W., & Ohashi, P. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.95 · Cited by 77
Economou, J. S., Belldegrun, A. S., Glaspy, J. A., Toloza, E. M., Figlin, R. A., Hobbs, J. A., Meldon, N., Kaboo, R., Tso, C. L., Miller, A. D., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118443 · Cited by 67
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Peng, L., Cohen, P. A., Kjærgaard, J., Plautz, G. E., Finke, J. H., Koski, G. K., Czerniecki, B. J., & Shu, S. (2001) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v21.i1-3.150 · Cited by 51
Abbott, A. (2002) · Nature · doi:10.1038/416470a · Cited by 34
Dendritic Cells for Specific Cancer Immunotherapy
Meidenbauer, N., Andreesen, R., & Mackensen, A. (2001) · Biological Chemistry · doi:10.1515/bc.2001.065 · Cited by 28
Self-citationMackensen, A., Wittnebel, S., Veelken, H., Noppen, C., Spagnoli, G. C., & Lindermann, A. (1999) · PubMed · Cited by 15
Self-citation
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
“Multiple solid tumor types includingmelanoma, RCC,NSCLC, thymoma, ovarian, and colorectal cancer co-opt this immune shield by expressing PD-L1 to generate an immunosuppressive tumor microenvironment and avoid T cell cytolysis (16, 17, 18).”
BackgroundPD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Metadata
- Authors
- Blank, C., Gajewski, T. F., & Mackensen, A.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2004-12-15
- Volume
- 54
- Issue
- 4
- Pages
- 307-314
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2108855090
- Cited by
- 637
- References
- 80
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.